首页 > 最新文献

Biomarker Insights最新文献

英文 中文
Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study. 甲泼尼龙对重症COVID-19患者炎症和凝血的影响:一项回顾性队列研究
IF 3.8 Q2 Medicine Pub Date : 2021-06-04 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211021647
Katja Tromp, Philip van der Zee, Casper Rokx, Jeroen van Kampen, Diederik Gommers, Henrik Endeman

Corticosteroids reduced mortality rate in patients with coronavirus disease 2019 (COVID-19). Previously, we hypothesized that corticosteroids mitigate the inflammation response resulting in reduced coagulation and thrombosis. In this retrospective study, we included 27 patients with COVID-19 that received high-dose corticosteroids (methylprednisolone 1000 mg i.v. daily for 3 days) for persistent respiratory failure or an excessive inflammation response. We found that inflammation, coagulation, and ventilation parameters improved significantly after methylprednisolone. The viral loads of SARS-CoV-2 remained stable or decreased. These results provides insight into the reduced mortality rate observed in patients with COVID-19 treated with corticosteroids.

糖皮质类固醇降低了2019冠状病毒病(COVID-19)患者的死亡率。以前,我们假设皮质类固醇减轻炎症反应,从而减少凝血和血栓形成。在这项回顾性研究中,我们纳入了27例因持续呼吸衰竭或过度炎症反应而接受大剂量皮质类固醇(甲基强的松龙1000 mg每日静脉注射,持续3天)治疗的COVID-19患者。我们发现甲强的松龙治疗后炎症、凝血和通气参数明显改善。SARS-CoV-2病毒载量保持稳定或下降。这些结果为使用皮质类固醇治疗的COVID-19患者观察到的死亡率降低提供了见解。
{"title":"Effect of Methylprednisolone on Inflammation and Coagulation in Patients with Severe COVID-19: A Retrospective Cohort Study.","authors":"Katja Tromp,&nbsp;Philip van der Zee,&nbsp;Casper Rokx,&nbsp;Jeroen van Kampen,&nbsp;Diederik Gommers,&nbsp;Henrik Endeman","doi":"10.1177/11772719211021647","DOIUrl":"https://doi.org/10.1177/11772719211021647","url":null,"abstract":"<p><p>Corticosteroids reduced mortality rate in patients with coronavirus disease 2019 (COVID-19). Previously, we hypothesized that corticosteroids mitigate the inflammation response resulting in reduced coagulation and thrombosis. In this retrospective study, we included 27 patients with COVID-19 that received high-dose corticosteroids (methylprednisolone 1000 mg i.v. daily for 3 days) for persistent respiratory failure or an excessive inflammation response. We found that inflammation, coagulation, and ventilation parameters improved significantly after methylprednisolone. The viral loads of SARS-CoV-2 remained stable or decreased. These results provides insight into the reduced mortality rate observed in patients with COVID-19 treated with corticosteroids.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211021647","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39095635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study. 蒽环类药物化疗后认知障碍的乳腺癌患者的细胞外囊泡蛋白质组:一项探索性研究
IF 3.8 Q2 Medicine Pub Date : 2021-05-24 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211018204
Yong Qin Koh, Ding Quan Ng, Chiu Chin Ng, Adrian Boey, Meng Wei, Siu Kwan Sze, Han Kiat Ho, Munjal Acharya, Charles L Limoli, Alexandre Chan

Cognitive impairment due to cancer and its therapy is a major concern among cancer patients and survivors. Extracellular vesicle (EVs) composition altered by cancer and chemotherapy may affect neurological processes such as neuroplasticity, potentially impacting the cognitive abilities of cancer patients and survivors. We investigated the EV proteome of breast cancer patients with and without cognitive impairment following anthracycline-based chemotherapy from longitudinally collected plasma. EVs were cup-shaped and positive for Flotillin-1 and TSG-101. We identified 517 differentially expressed EV proteins between the cognitive impaired and non-impaired groups during and post-chemotherapy. The observed decreased expression of p2X purinoceptor, cofilin-1, ADAM 10, and dynamin-1 in the plasma EVs of the cognitive impaired group may suggest alterations in the mechanisms underlying synaptic plasticity. The reduced expression of tight junction proteins among cognitive-impaired patients may imply weakening of the blood-brain barrier. These EV protein signatures may serve as a fingerprint that underscores the mechanisms underlying cognitive impairment in cancer patients and survivors.

癌症引起的认知障碍及其治疗是癌症患者和幸存者关注的主要问题。癌症和化疗改变细胞外囊泡(EVs)组成可能影响神经过程,如神经可塑性,潜在地影响癌症患者和幸存者的认知能力。我们从纵向收集的血浆中研究了有和没有认知障碍的乳腺癌患者在蒽环类药物化疗后的EV蛋白质组。电动汽车呈杯状,Flotillin-1和TSG-101阳性。我们在化疗期间和化疗后的认知受损组和非认知受损组之间鉴定了517种差异表达的EV蛋白。认知障碍组血浆ev中p2X嘌呤受体、cofilin-1、ADAM - 10和动力蛋白-1的表达减少可能提示突触可塑性机制的改变。认知障碍患者紧密连接蛋白表达的减少可能意味着血脑屏障的减弱。这些EV蛋白特征可以作为一个指纹,强调癌症患者和幸存者认知障碍的潜在机制。
{"title":"Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study.","authors":"Yong Qin Koh,&nbsp;Ding Quan Ng,&nbsp;Chiu Chin Ng,&nbsp;Adrian Boey,&nbsp;Meng Wei,&nbsp;Siu Kwan Sze,&nbsp;Han Kiat Ho,&nbsp;Munjal Acharya,&nbsp;Charles L Limoli,&nbsp;Alexandre Chan","doi":"10.1177/11772719211018204","DOIUrl":"https://doi.org/10.1177/11772719211018204","url":null,"abstract":"<p><p>Cognitive impairment due to cancer and its therapy is a major concern among cancer patients and survivors. Extracellular vesicle (EVs) composition altered by cancer and chemotherapy may affect neurological processes such as neuroplasticity, potentially impacting the cognitive abilities of cancer patients and survivors. We investigated the EV proteome of breast cancer patients with and without cognitive impairment following anthracycline-based chemotherapy from longitudinally collected plasma. EVs were cup-shaped and positive for Flotillin-1 and TSG-101. We identified 517 differentially expressed EV proteins between the cognitive impaired and non-impaired groups during and post-chemotherapy. The observed decreased expression of p2X purinoceptor, cofilin-1, ADAM 10, and dynamin-1 in the plasma EVs of the cognitive impaired group may suggest alterations in the mechanisms underlying synaptic plasticity. The reduced expression of tight junction proteins among cognitive-impaired patients may imply weakening of the blood-brain barrier. These EV protein signatures may serve as a fingerprint that underscores the mechanisms underlying cognitive impairment in cancer patients and survivors.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211018204","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38995358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid. 马德里一项与COVID-19住院患者预后不良相关的IL-6和其他生物标志物
IF 3.8 Q2 Medicine Pub Date : 2021-05-24 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013363
Encarnación Donoso-Navarro, Ignacio Arribas Gómez, Francisco A Bernabeu-Andreu
Objectives: There are several published works on the prognostic value of biomarkers in relation to the severity or fatal outcome of coronavirus disease 2019 (COVID-19). In Spain, the second European country in incidence of the disease at the time of data collection, there are few studies that include both laboratory parameters and clinical parameters. Our aim is to study the relationship of a wide series of biomarkers with admission to intensive care and death in a hospital in the Autonomous Community of Madrid (Spain), with special attention to IL-6 due to its role in the systemic inflammatory response associated with a worse prognosis of the disease. Methods: Data were collected from 546 hospitalized patients with COVID-19. All of them had IL-6 results, in addition to other biochemical and haematological parameters. The difference of the medians for the selected parameters between the groups (ICU vs non-ICU, dead vs survivors) was studied using a Mann-Whitney analysis. The independent variables that predicted death were studied using a Cox proportional hazard regression model. Results: Higher age and blood concentrations of ALT, creatinine, CK, cTnI, LDH, NT-proBNP, CRP, IL-6, leucocyte count and D-dimer together with lower blood concentrations of albumin and lymphocyte count were associated with mortality in univariate analysis. Age, LDH, IL-6 and lymphocyte count remained associated with death in multivariate analysis. Conclusions: Age, LDH, IL-6 and lymphocyte count, as independent predictors of death, could be used to establish more aggressive therapies in COVID-19 patients.
目的:已经发表了几篇关于生物标志物与2019冠状病毒病(COVID-19)严重程度或致命结局相关的预后价值的论文。西班牙是收集数据时该病发病率第二高的欧洲国家,但很少有研究同时包括实验室参数和临床参数。我们的目的是研究一系列生物标志物与马德里自治区(西班牙)一家医院重症监护和死亡的关系,特别关注IL-6,因为它在与疾病预后较差相关的全身炎症反应中起作用。方法:收集546例新冠肺炎住院患者资料。除其他生化和血液学参数外,所有患者均有IL-6结果。采用Mann-Whitney分析研究两组(ICU与非ICU、死亡与幸存者)所选参数中位数的差异。使用Cox比例风险回归模型研究预测死亡的自变量。结果:在单因素分析中,较高的年龄和血中ALT、肌酐、CK、cTnI、LDH、NT-proBNP、CRP、IL-6、白细胞计数和d -二聚体浓度以及较低的血中白蛋白浓度和淋巴细胞计数与死亡率相关。在多变量分析中,年龄、LDH、IL-6和淋巴细胞计数仍与死亡相关。结论:年龄、LDH、IL-6和淋巴细胞计数作为死亡的独立预测因子,可用于建立更积极的COVID-19患者治疗方法。
{"title":"IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid.","authors":"Encarnación Donoso-Navarro,&nbsp;Ignacio Arribas Gómez,&nbsp;Francisco A Bernabeu-Andreu","doi":"10.1177/11772719211013363","DOIUrl":"https://doi.org/10.1177/11772719211013363","url":null,"abstract":"Objectives: There are several published works on the prognostic value of biomarkers in relation to the severity or fatal outcome of coronavirus disease 2019 (COVID-19). In Spain, the second European country in incidence of the disease at the time of data collection, there are few studies that include both laboratory parameters and clinical parameters. Our aim is to study the relationship of a wide series of biomarkers with admission to intensive care and death in a hospital in the Autonomous Community of Madrid (Spain), with special attention to IL-6 due to its role in the systemic inflammatory response associated with a worse prognosis of the disease. Methods: Data were collected from 546 hospitalized patients with COVID-19. All of them had IL-6 results, in addition to other biochemical and haematological parameters. The difference of the medians for the selected parameters between the groups (ICU vs non-ICU, dead vs survivors) was studied using a Mann-Whitney analysis. The independent variables that predicted death were studied using a Cox proportional hazard regression model. Results: Higher age and blood concentrations of ALT, creatinine, CK, cTnI, LDH, NT-proBNP, CRP, IL-6, leucocyte count and D-dimer together with lower blood concentrations of albumin and lymphocyte count were associated with mortality in univariate analysis. Age, LDH, IL-6 and lymphocyte count remained associated with death in multivariate analysis. Conclusions: Age, LDH, IL-6 and lymphocyte count, as independent predictors of death, could be used to establish more aggressive therapies in COVID-19 patients.","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211013363","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38995357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4. 血清微纤维相关蛋白的昼夜、周与周和体育锻炼引起的变化
IF 3.8 Q2 Medicine Pub Date : 2021-05-14 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211016359
Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen

Serum microfibrillar-associated protein 4 (sMFAP4) has been investigated as a biomarker for various diseases and is demonstrated to show significant gradual increase with severity of liver fibrosis. Ideal biomarkers used for disease diagnosis or prognosis should display deviating levels in affected individuals only and be robust to factors unrelated to the disease. Here we show the impact of normal physiological variation of sMFAP4 by characterizing the circadian variation, week-to-week variation, and physical exercise-induced levels. Serum samples from 3 groups of healthy volunteers were drawn: 7 times during a 24-hour period, 5 times during a 3-week period, and before and after a standardized physical exercise challenge. sMFAP4 was determined by AlphaLISA. Statistical analysis was performed using mixed effects modeling of repeated measurements. Circadian variation of sMFAP4 was demonstrated, with time of peak and nadir values depending on age and gender. For males, the peak values were observed during nighttime whereas for females, peak values were observed in the morning. Individual sMFAP4 levels remained stable over a period of 3 weeks and physical exercise inferred a mild negative influence. In conclusion, the circadian sMFAP4 variation was significant, and the levels could be influenced by physical activity. However, these variations were of limited magnitude relative to previously observed disease-induced levels in support of the biomarker potential of sMFAP4.

血清微纤维相关蛋白4 (sMFAP4)已被研究作为多种疾病的生物标志物,并被证明随着肝纤维化的严重程度逐渐增加。用于疾病诊断或预后的理想生物标志物应仅在受影响个体中显示偏离水平,并且对与疾病无关的因素保持稳健。在这里,我们通过表征昼夜变化、周间变化和体育锻炼诱导的水平来展示sMFAP4正常生理变化的影响。抽取3组健康志愿者的血清样本:在24小时内抽取7次,在3周内抽取5次,以及在标准化体育锻炼挑战之前和之后抽取。采用AlphaLISA检测sMFAP4。采用重复测量的混合效应模型进行统计分析。sMFAP4表现出昼夜变化,峰值和最低点的时间取决于年龄和性别。雄性的峰值出现在夜间,雌性的峰值出现在早晨。个体sMFAP4水平在3周内保持稳定,体育锻炼推断出轻微的负面影响。综上所述,sMFAP4的昼夜变化是显著的,其水平可能受到身体活动的影响。然而,与之前观察到的疾病诱导水平相比,这些变化的幅度有限,这支持了sMFAP4的生物标志物潜力。
{"title":"Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4.","authors":"Susanne Gjørup Sækmose,&nbsp;René Holst,&nbsp;Tine Lottenburger,&nbsp;Henriette Ytting,&nbsp;Hans Jørgen Nielsen,&nbsp;Peter Junker,&nbsp;Anders Schlosser,&nbsp;Grith Lykke Sorensen","doi":"10.1177/11772719211016359","DOIUrl":"https://doi.org/10.1177/11772719211016359","url":null,"abstract":"<p><p>Serum microfibrillar-associated protein 4 (sMFAP4) has been investigated as a biomarker for various diseases and is demonstrated to show significant gradual increase with severity of liver fibrosis. Ideal biomarkers used for disease diagnosis or prognosis should display deviating levels in affected individuals only and be robust to factors unrelated to the disease. Here we show the impact of normal physiological variation of sMFAP4 by characterizing the circadian variation, week-to-week variation, and physical exercise-induced levels. Serum samples from 3 groups of healthy volunteers were drawn: 7 times during a 24-hour period, 5 times during a 3-week period, and before and after a standardized physical exercise challenge. sMFAP4 was determined by AlphaLISA. Statistical analysis was performed using mixed effects modeling of repeated measurements. Circadian variation of sMFAP4 was demonstrated, with time of peak and nadir values depending on age and gender. For males, the peak values were observed during nighttime whereas for females, peak values were observed in the morning. Individual sMFAP4 levels remained stable over a period of 3 weeks and physical exercise inferred a mild negative influence. In conclusion, the circadian sMFAP4 variation was significant, and the levels could be influenced by physical activity. However, these variations were of limited magnitude relative to previously observed disease-induced levels in support of the biomarker potential of sMFAP4.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211016359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38936847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches. 通过蛋白质组学和代谢组学方法发现多发性硬化症生物标志物。
IF 3.8 Q2 Medicine Pub Date : 2021-05-06 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013352
Ameneh Jafari, Amirhesam Babajani, Mostafa Rezaei-Tavirani

Multiple sclerosis (MS) is an autoimmune inflammatory disorder of the central nervous system (CNS) resulting in demyelination and axonal loss in the brain and spinal cord. The precise pathogenesis and etiology of this complex disease are still a mystery. Despite many studies that have been aimed to identify biomarkers, no protein marker has yet been approved for MS. There is urgently needed for biomarkers, which could clarify pathology, monitor disease progression, response to treatment, and prognosis in MS. Proteomics and metabolomics analysis are powerful tools to identify putative and novel candidate biomarkers. Different human compartments analysis using proteomics, metabolomics, and bioinformatics approaches has generated new information for further clarification of MS pathology, elucidating the mechanisms of the disease, finding new targets, and monitoring treatment response. Overall, omics approaches can develop different therapeutic and diagnostic aspects of complex disorders such as multiple sclerosis, from biomarker discovery to personalized medicine.

多发性硬化症(MS)是一种中枢神经系统(CNS)自身免疫性炎症性疾病,会导致大脑和脊髓脱髓鞘和轴突丢失。这种复杂疾病的确切发病机制和病因至今仍是一个谜。尽管有许多研究旨在确定生物标志物,但至今还没有一种蛋白质标志物被批准用于多发性硬化症。目前迫切需要生物标志物,以明确多发性硬化症的病理、监测疾病进展、治疗反应和预后。蛋白质组学和代谢组学分析是确定潜在和新型候选生物标志物的有力工具。利用蛋白质组学、代谢组学和生物信息学方法对不同的人体分区进行分析,为进一步阐明多发性硬化症的病理、阐明疾病的机制、寻找新的靶点和监测治疗反应提供了新的信息。总之,从生物标记物的发现到个性化医疗,omics 方法可以为多发性硬化症等复杂疾病开发出不同的治疗和诊断方法。
{"title":"Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches.","authors":"Ameneh Jafari, Amirhesam Babajani, Mostafa Rezaei-Tavirani","doi":"10.1177/11772719211013352","DOIUrl":"10.1177/11772719211013352","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is an autoimmune inflammatory disorder of the central nervous system (CNS) resulting in demyelination and axonal loss in the brain and spinal cord. The precise pathogenesis and etiology of this complex disease are still a mystery. Despite many studies that have been aimed to identify biomarkers, no protein marker has yet been approved for MS. There is urgently needed for biomarkers, which could clarify pathology, monitor disease progression, response to treatment, and prognosis in MS. Proteomics and metabolomics analysis are powerful tools to identify putative and novel candidate biomarkers. Different human compartments analysis using proteomics, metabolomics, and bioinformatics approaches has generated new information for further clarification of MS pathology, elucidating the mechanisms of the disease, finding new targets, and monitoring treatment response. Overall, omics approaches can develop different therapeutic and diagnostic aspects of complex disorders such as multiple sclerosis, from biomarker discovery to personalized medicine.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e8/10.1177_11772719211013352.PMC8114757.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38933381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme. 精神高于物质:多形性胶质母细胞瘤死后脑生物银行面临的挑战。
IF 3.8 Q2 Medicine Pub Date : 2021-04-30 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211013359
Cassandra Griffin, Ricardo Vilain, Simon King, Sandy Nixon, Alisha Gooley, Samara Bray, James Lynam, Marjorie M Walker, Rodney J Scott, Christine Paul

Over the past 10 years, there has been limited progress for the treatment of brain cancer and outcomes for patients are not much improved. For brain cancer researchers, a major obstacle to biomarker driven research is limited access to brain cancer tissue for research purposes. The Mark Hughes Foundation Brain Biobank is one of the first post-mortem adult brain banks in Australia to operate with protocols specifically developed for brain cancer. Located within the Hunter New England Local Health District and operated by Hunter Cancer Biobank, the boundaries of service provided by the Brain Bank extend well into the surrounding regional and rural areas of the Local Health District and beyond. Brain cancer biobanking is challenging. There are conflicting international guidelines for best practice and unanswered questions relating to scientific, psychosocial and operational practices. To address this challenge, a best practice model was developed, informed by a consensus of existing data but with consideration of the difficulties associated with operating in regional or resource poor settings. The regional application of this model was challenged following the presentation of a donor located in a remote area, 380km away from the biobank. This required biobank staff to overcome numerous obstacles including long distance patient transport, lack of palliative care staff, death in the home and limited rural outreach services. Through the establishment of shared goals, contingency planning and the development of an informal infrastructure, the donation was facilitated within the required timeframe. This experience demonstrates the importance of collaboration and networking to overcome resource insufficiency and geographical challenges in rural cancer research programmes.

在过去的10年里,脑癌的治疗进展有限,患者的预后也没有多大改善。对于脑癌研究人员来说,生物标志物驱动研究的一个主要障碍是为研究目的获取脑癌组织的途径有限。马克·休斯基金会脑生物银行是澳大利亚首批按照专门为脑癌制定的协议运作的成人死后脑库之一。脑库位于亨特新英格兰地方卫生区内,由亨特癌症生物银行运营,其服务范围延伸至当地卫生区的周边地区和农村地区,甚至更远。脑癌生物银行具有挑战性。关于最佳做法的国际准则相互矛盾,在科学、社会心理和业务实践方面也存在未解决的问题。为了应对这一挑战,开发了一个最佳实践模型,该模型基于对现有数据的共识,但考虑到在区域或资源贫乏环境中开展业务的困难。在距离生物库380公里远的偏远地区出现了一名捐赠者后,这一模式的区域应用受到了挑战。这就要求生物库工作人员克服许多障碍,包括远距离运送病人、缺乏姑息治疗工作人员、家中死亡和农村外联服务有限。通过确定共同目标、制定应急计划和发展非正式基础设施,在规定的时限内促进了捐赠。这一经验表明协作和建立网络对于克服农村癌症研究规划中的资源不足和地理挑战的重要性。
{"title":"Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme.","authors":"Cassandra Griffin,&nbsp;Ricardo Vilain,&nbsp;Simon King,&nbsp;Sandy Nixon,&nbsp;Alisha Gooley,&nbsp;Samara Bray,&nbsp;James Lynam,&nbsp;Marjorie M Walker,&nbsp;Rodney J Scott,&nbsp;Christine Paul","doi":"10.1177/11772719211013359","DOIUrl":"https://doi.org/10.1177/11772719211013359","url":null,"abstract":"<p><p>Over the past 10 years, there has been limited progress for the treatment of brain cancer and outcomes for patients are not much improved. For brain cancer researchers, a major obstacle to biomarker driven research is limited access to brain cancer tissue for research purposes. The Mark Hughes Foundation Brain Biobank is one of the first post-mortem adult brain banks in Australia to operate with protocols specifically developed for brain cancer. Located within the Hunter New England Local Health District and operated by Hunter Cancer Biobank, the boundaries of service provided by the Brain Bank extend well into the surrounding regional and rural areas of the Local Health District and beyond. Brain cancer biobanking is challenging. There are conflicting international guidelines for best practice and unanswered questions relating to scientific, psychosocial and operational practices. To address this challenge, a best practice model was developed, informed by a consensus of existing data but with consideration of the difficulties associated with operating in regional or resource poor settings. The regional application of this model was challenged following the presentation of a donor located in a remote area, 380km away from the biobank. This required biobank staff to overcome numerous obstacles including long distance patient transport, lack of palliative care staff, death in the home and limited rural outreach services. Through the establishment of shared goals, contingency planning and the development of an informal infrastructure, the donation was facilitated within the required timeframe. This experience demonstrates the importance of collaboration and networking to overcome resource insufficiency and geographical challenges in rural cancer research programmes.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211013359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39930049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Quality Considerations When Using Tissue Samples for Biomarker Studies in Cancer Research. 在癌症研究中使用组织样本进行生物标记物研究时的质量考虑因素。
IF 3.8 Q2 Medicine Pub Date : 2021-04-20 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211009513
Valerie Speirs

Tissue obtained from biobanks is frequently employed in biomarker studies. Biomarkers define objective, measurable characteristics of biological and biomedical procedures and have been used as indicators of clinical outcome. This article outlines some of the steps scientists should consider when embarking on biomarker research in cancer research using samples from biobanks and the importance and challenges of linking clinical data to biological samples.

生物标志物研究经常使用从生物库中获取的组织。生物标志物定义了生物和生物医学过程中客观的、可测量的特征,并已被用作临床结果的指标。本文概述了科学家在癌症研究中使用生物库样本开展生物标记物研究时应考虑的一些步骤,以及将临床数据与生物样本联系起来的重要性和挑战。
{"title":"Quality Considerations When Using Tissue Samples for Biomarker Studies in Cancer Research.","authors":"Valerie Speirs","doi":"10.1177/11772719211009513","DOIUrl":"10.1177/11772719211009513","url":null,"abstract":"<p><p>Tissue obtained from biobanks is frequently employed in biomarker studies. Biomarkers define objective, measurable characteristics of biological and biomedical procedures and have been used as indicators of clinical outcome. This article outlines some of the steps scientists should consider when embarking on biomarker research in cancer research using samples from biobanks and the importance and challenges of linking clinical data to biological samples.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38877424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children. 评估选定标记物在诊断儿童慢性肾脏病中的实用性。
IF 3.8 Q2 Medicine Pub Date : 2021-04-20 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211011173
Agata Będzichowska, Katarzyna Jobs, Małgorzata Kloc, Anna Bujnowska, Bolesław Kalicki

Introduction: The kidney deterioration, which starts in childhood often leads to end-stage renal failure in the future. Therefore, searching for an early, sensitive, and specific biomarkers became a paramount for chronic kidney disease diagnosis. The aim of this study was the assessment of markers: KIM-1, FGF-23, NAG, NGAL, and uromodulin for diagnosis of preclinical phase of the disease in children.

Patients and methods: 59 children (15 boys, 44 girls from 6 months to 17 years old) with kidney disorders, which had clinical indications for renoscintigraphy, were included in the study. All patients were divided depending on the result of renoscintigraphy (renal scarring vs normal kidney picture) and depending on the level of estimated glomerular filtration rate (glomerular hyperfiltration vs normal filtration rate). The concentration of uromoduline, KIM-1, FGF-23, NAG, and NGAL in serum and of NGAL and uromoduline in urine were measured in all studied groups.

Results: The children with glomerular hyperfiltration had a statistically significantly higher serum values of FGF-23 and NGAL than the children with normal filtration rate (P < .05). There were no statistically significant differences in serum concentrations of tested markers in children with renal scars in comparison to children with normal renal image. There was no statistically significant difference in the concentration of tested markers in urine.

Conclusions: The study confirmed the possible usefulness of FGF-23 and NGAL in detecting the preclinical-stage of renal disease associated with glomerular hyperfiltration in children. The study do not allow to indicate markers, which could be useful in the early diagnosis of kidney damage visible in the scintigraphic examination.

简介儿童时期开始的肾功能衰退往往会导致未来的终末期肾衰竭。因此,寻找早期、敏感和特异的生物标志物已成为慢性肾脏病诊断的首要任务。本研究的目的是评估以下标志物:患者和方法:59 名患有肾脏疾病的儿童(15 名男孩,44 名女孩,年龄在 6 个月至 17 岁之间)被纳入研究,这些儿童具有肾镜成像的临床指征。所有患者根据肾镜检查结果(肾瘢痕与正常肾脏图像)和估计肾小球滤过率水平(肾小球高滤过与正常滤过率)进行分类。所有研究组均测定了血清中尿嘧啶、KIM-1、FGF-23、NAG 和 NGAL 的浓度,以及尿液中 NGAL 和尿嘧啶的浓度:结果:肾小球高滤过率儿童血清中的 FGF-23 和 NGAL 值明显高于滤过率正常儿童(P研究证实,FGF-23 和 NGAL 可能有助于检测儿童肾小球高滤过相关肾病的临床前阶段。该研究无法指出哪些标记物有助于早期诊断闪烁成像检查中可见的肾脏损伤。
{"title":"The Assessment of the Usefulness of Selected Markers in the Diagnosis of Chronic Kidney Disease in Children.","authors":"Agata Będzichowska, Katarzyna Jobs, Małgorzata Kloc, Anna Bujnowska, Bolesław Kalicki","doi":"10.1177/11772719211011173","DOIUrl":"10.1177/11772719211011173","url":null,"abstract":"<p><strong>Introduction: </strong>The kidney deterioration, which starts in childhood often leads to end-stage renal failure in the future. Therefore, searching for an early, sensitive, and specific biomarkers became a paramount for chronic kidney disease diagnosis. The aim of this study was the assessment of markers: KIM-1, FGF-23, NAG, NGAL, and uromodulin for diagnosis of preclinical phase of the disease in children.</p><p><strong>Patients and methods: </strong>59 children (15 boys, 44 girls from 6 months to 17 years old) with kidney disorders, which had clinical indications for renoscintigraphy, were included in the study. All patients were divided depending on the result of renoscintigraphy (renal scarring vs normal kidney picture) and depending on the level of estimated glomerular filtration rate (glomerular hyperfiltration vs normal filtration rate). The concentration of uromoduline, KIM-1, FGF-23, NAG, and NGAL in serum and of NGAL and uromoduline in urine were measured in all studied groups.</p><p><strong>Results: </strong>The children with glomerular hyperfiltration had a statistically significantly higher serum values of FGF-23 and NGAL than the children with normal filtration rate (<i>P</i> < .05). There were no statistically significant differences in serum concentrations of tested markers in children with renal scars in comparison to children with normal renal image. There was no statistically significant difference in the concentration of tested markers in urine.</p><p><strong>Conclusions: </strong>The study confirmed the possible usefulness of FGF-23 and NGAL in detecting the preclinical-stage of renal disease associated with glomerular hyperfiltration in children. The study do not allow to indicate markers, which could be useful in the early diagnosis of kidney damage visible in the scintigraphic examination.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/13/10.1177_11772719211011173.PMC8060753.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38877425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms. 使用两种不同的多重免疫分析平台分析脑肿瘤患者与健康人血浆中的细胞因子谱
IF 3.8 Q2 Medicine Pub Date : 2021-03-30 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211006666
Diane Elizabeth Bender, Maximilian O Schaettler, Kathleen Cf Sheehan, Tanner M Johanns, Gavin P Dunn

We compared the performance of two 96-well multiplex immunoassay platforms in assessing plasma cytokine concentrations in patients with glioblastoma (GBM; n = 27), individuals with melanoma, breast or lung cancer metastases to the brain (n = 17), and healthy volunteers (n = 11). Assays included a bead-based fluorescence MILLIPLEX® assay/Luminex (LMX) platform and 4 planar electrochemiluminescence kits from Meso Scale Discovery (MSD). The LMX kit evaluated 21 cytokines and the 3 MSD kits evaluated 20 cytokines in total, with 19 overlapping human cytokines between platforms (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β, MIP-3α, TNFα). The MSD platform had lower LLoQs (lower limits of quantification) than LMX for 17/19 cytokines, and higher LLoQs for IFN-γ and IL-21. The ULoQs were higher in LMX versus MSD assays for 17/19 shared analytes, but lower than MSD for IL-17A and IL-21. With LMX, all 19 shared analytes were quantifiable in each of 55 samples. Although MSD recombinant protein standard curves indicated lower LLoQs than LMX for most cytokines, MSD detected 7/19 (37%) native analytes in <75% of samples, including 0% detection for IL-21 and 8% for IL-23. The LMX platform categorized identical samples at greater concentrations than the MSD system for most analytes (MIP-1β the sole exception), sometimes by orders of magnitude. This mismatched quantification paradigm was supported by Bland-Altman analysis. LMX identified significantly elevated levels of 10 of 19 circulating cytokines in GBM: GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21, IL-23, MIP-1α, and MIP-3α, consistent with prior findings and confirming the utility of applying appropriate multiplex immunoassay technologies toward developing a cytokine signature profile for GBM.

我们比较了两种96孔多重免疫分析平台在评估胶质母细胞瘤(GBM;N = 27)、黑色素瘤、乳腺癌或肺癌转移到大脑的个体(N = 17)和健康志愿者(N = 11)。实验包括一个基于珠状荧光MILLIPLEX®检测/Luminex (LMX)平台和4个来自Meso Scale Discovery (MSD)的平面电化学发光试剂盒。LMX试剂盒检测了21种细胞因子,MSD试剂盒检测了20种细胞因子,其中有19种人类细胞因子在平台间重叠(GM-CSF、IFNγ、IL-1β、IL-2、IL-4、IL-5、IL-6、IL-7、IL-8、IL-10、IL-12p70、IL-13、IL-17A、IL-21、IL-23、MIP-1α、MIP-1β、MIP-3α、TNFα)。MSD平台对17/19细胞因子的lloq(定量下限)低于LMX,对IFN-γ和IL-21的lloq更高。对于17/19共享分析物,LMX的uloq高于MSD,但IL-17A和IL-21的uloq低于MSD。使用LMX, 55个样品中的所有19种共享分析物均可量化。虽然MSD重组蛋白标准曲线显示大多数细胞因子的lloq低于LMX,但MSD检测到7/19(37%)的天然分析物
{"title":"Cytokine Profiling in Plasma from Patients with Brain Tumors Versus Healthy Individuals using 2 Different Multiplex Immunoassay Platforms.","authors":"Diane Elizabeth Bender,&nbsp;Maximilian O Schaettler,&nbsp;Kathleen Cf Sheehan,&nbsp;Tanner M Johanns,&nbsp;Gavin P Dunn","doi":"10.1177/11772719211006666","DOIUrl":"https://doi.org/10.1177/11772719211006666","url":null,"abstract":"<p><p>We compared the performance of two 96-well multiplex immunoassay platforms in assessing plasma cytokine concentrations in patients with glioblastoma (GBM; n = 27), individuals with melanoma, breast or lung cancer metastases to the brain (n = 17), and healthy volunteers (n = 11). Assays included a bead-based fluorescence MILLIPLEX<sup>®</sup> assay/Luminex (LMX) platform and 4 planar electrochemiluminescence kits from Meso Scale Discovery (MSD). The LMX kit evaluated 21 cytokines and the 3 MSD kits evaluated 20 cytokines in total, with 19 overlapping human cytokines between platforms (GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, MIP-1α, MIP-1β, MIP-3α, TNFα). The MSD platform had lower LLoQs (lower limits of quantification) than LMX for 17/19 cytokines, and higher LLoQs for IFN-γ and IL-21. The ULoQs were higher in LMX versus MSD assays for 17/19 shared analytes, but lower than MSD for IL-17A and IL-21. With LMX, all 19 shared analytes were quantifiable in each of 55 samples. Although MSD recombinant protein standard curves indicated lower LLoQs than LMX for most cytokines, MSD detected 7/19 (37%) native analytes in <75% of samples, including 0% detection for IL-21 and 8% for IL-23. The LMX platform categorized identical samples at greater concentrations than the MSD system for most analytes (MIP-1β the sole exception), sometimes by orders of magnitude. This mismatched quantification paradigm was supported by Bland-Altman analysis. LMX identified significantly elevated levels of 10 of 19 circulating cytokines in GBM: GM-CSF, IFN-γ, IL-1β, IL-5, IL-10, IL-17A, IL-21, IL-23, MIP-1α, and MIP-3α, consistent with prior findings and confirming the utility of applying appropriate multiplex immunoassay technologies toward developing a cytokine signature profile for GBM.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211006666","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25591522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability. 与时俱进:健康科学联盟(HSA)生物库,可持续发展之路。
IF 3.8 Q2 Medicine Pub Date : 2021-03-27 eCollection Date: 2021-01-01 DOI: 10.1177/11772719211005745
Carmel M Quinn, Mamta Porwal, Nicola S Meagher, Anusha Hettiaratchi, Carl Power, Jitendra Jonnaggadala, Sue McCullough, Stephanie Macmillan, Katrina Tang, Winston Liauw, David Goldstein, Nikolajs Zeps, Philip J Crowe

Human biobanks are recognised as vital components of translational research infrastructure. With the growth in personalised and precision medicine, and the associated expansion of biomarkers and novel therapeutics under development, it is critical that researchers can access a strong collection of patient biospecimens, annotated with clinical data. Biobanks globally are undertaking transformation of their operating models in response to changing research needs; transition from a 'classic' model representing a largely retrospective collection of pre-defined specimens to a more targeted, prospective collection model, although there remains a research need for both models to co-exist. Here we introduce the Health Science Alliance (HSA) Biobank, established in 2012 as a classic biobank, now transitioning to a hybrid operational model. Some of the past and current challenges encountered are discussed including clinical annotation, specimen utilisation and biobank sustainability, along with the measures the HSA Biobank is taking to address these challenges. We describe new directions being explored, going beyond traditional specimen collection into areas involving bioimages, microbiota and live cell culture. The HSA Biobank is working in collaboration with clinicians, pathologists and researchers, piloting a sustainable, robust platform with the potential to integrate future needs.

人类生物库被认为是转化研究基础设施的重要组成部分。随着个性化和精准医疗的发展,以及生物标志物和正在开发的新疗法的相关扩展,研究人员能够获得大量患者生物标本,并附有临床数据注释,这一点至关重要。全球生物银行正在进行运营模式的转型,以应对不断变化的研究需求;从一个“经典”模型过渡到一个更有针对性的、前瞻性的收集模型,尽管这两种模型仍然需要共存。健康科学联盟(HSA)生物样本库成立于2012年,是一个经典的生物样本库,现在正在向混合运营模式过渡。讨论了一些过去和当前遇到的挑战,包括临床注释,标本利用和生物库的可持续性,以及HSA生物库正在采取的措施来应对这些挑战。我们描述了正在探索的新方向,超越传统的标本收集,进入涉及生物图像,微生物群和活细胞培养的领域。HSA生物库正在与临床医生、病理学家和研究人员合作,试点一个可持续的、强大的平台,有可能整合未来的需求。
{"title":"Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability.","authors":"Carmel M Quinn,&nbsp;Mamta Porwal,&nbsp;Nicola S Meagher,&nbsp;Anusha Hettiaratchi,&nbsp;Carl Power,&nbsp;Jitendra Jonnaggadala,&nbsp;Sue McCullough,&nbsp;Stephanie Macmillan,&nbsp;Katrina Tang,&nbsp;Winston Liauw,&nbsp;David Goldstein,&nbsp;Nikolajs Zeps,&nbsp;Philip J Crowe","doi":"10.1177/11772719211005745","DOIUrl":"https://doi.org/10.1177/11772719211005745","url":null,"abstract":"<p><p>Human biobanks are recognised as vital components of translational research infrastructure. With the growth in personalised and precision medicine, and the associated expansion of biomarkers and novel therapeutics under development, it is critical that researchers can access a strong collection of patient biospecimens, annotated with clinical data. Biobanks globally are undertaking transformation of their operating models in response to changing research needs; transition from a 'classic' model representing a largely retrospective collection of pre-defined specimens to a more targeted, prospective collection model, although there remains a research need for both models to co-exist. Here we introduce the Health Science Alliance (HSA) Biobank, established in 2012 as a classic biobank, now transitioning to a hybrid operational model. Some of the past and current challenges encountered are discussed including clinical annotation, specimen utilisation and biobank sustainability, along with the measures the HSA Biobank is taking to address these challenges. We describe new directions being explored, going beyond traditional specimen collection into areas involving bioimages, microbiota and live cell culture. The HSA Biobank is working in collaboration with clinicians, pathologists and researchers, piloting a sustainable, robust platform with the potential to integrate future needs.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2021-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11772719211005745","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39930047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
期刊
Biomarker Insights
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1